Search results
Results from the WOW.Com Content Network
Trazodone is usually used at a dosage of 150 to 300 mg/day for the treatment of depression. [ 17 ] [ 13 ] Lower doses have also been used to augment other antidepressants or when initiating therapy. [ 17 ] [ 13 ] Higher doses, up to 600 mg/day, have been used in more severe cases of depression (in hospitalized patients, for example). [ 29 ]
Rare (<0.1%) adverse effects include: Urinary retention; Prolonged QT interval; Torsades de Pointes; Ataxia; Breast enlargement or engorgement; Lactation; Cardiospasm
Chemical structure of the serotonin antagonist and reuptake inhibitor trazodone.. Serotonin antagonist and reuptake inhibitors (SARIs) are a class of drugs used mainly as antidepressants, but also as anxiolytics and hypnotics.
DailyMed is a website operated by the U.S. National Library of Medicine (NLM) to publish up-to-date and accurate drug labels (also called a "package insert") to health care providers and the general public. The contents of DailyMed is provided and updated daily by the U.S. Food and Drug Administration (FDA). The FDA in turn collects this ...
An atypical antidepressant is any antidepressant medication that acts in a manner that is different from that of most other antidepressants. Atypical antidepressants include agomelatine, bupropion, iprindole, mianserin, mirtazapine, nefazodone, opipramol, tianeptine, and trazodone.
The dose should be increased after a minimum of 3 days up to approximately 1.2 mg/kg daily (target dose) as a single or two divided doses (in the morning and late afternoon). For children older than 6 years old, over 70 kg, acute treatment should be started with 40 mg/day orally and increased up to 80 mg/day after a minimum of 3 days.
Xywav is a medication used to treat cataplexy or excessive daytime sleepiness. [2] [3] It contains a mixture of the oxybate salts calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate. [2]
Tasimelteon, sold under the brand name Hetlioz, is a medication approved by the U.S. Food and Drug Administration (FDA) [3] in January 2014, for the treatment of non-24-hour sleep–wake disorder (also called non-24, N24 and N24HSWD). [4]